Genus Given Buy Rating at Liberum Capital (GNS)
Genus (LON:GNS)‘s stock had its “buy” rating reiterated by equities research analysts at Liberum Capital in a research note issued to investors on Friday, AnalystRatingsNetwork.com reports. They currently have a GBX 1,550 ($25.42) target price on the stock. Liberum Capital’s price objective would indicate a potential upside of 11.83% from the company’s current price.
Shares of Genus (LON:GNS) traded up 1.02% during mid-day trading on Friday, hitting GBX 1386.00. The stock had a trading volume of 23,723 shares. Genus has a 52-week low of GBX 1178.00 and a 52-week high of GBX 1609.00. The stock’s 50-day moving average is GBX 1266. and its 200-day moving average is GBX 1340.56. The company’s market cap is £837.8 million.
A number of other firms have also recently commented on GNS. Analysts at Nplus1 Brewin cut their price target on shares of Genus from GBX 1,357 ($22.26) to GBX 1,255 ($20.58) in a research note to investors on Wednesday, December 4th. They now have a “hold” rating on the stock. Separately, analysts at N+1 Singer cut their price target on shares of Genus from GBX 1,357 ($22.26) to GBX 1,255 ($20.58) in a research note to investors on Wednesday, December 4th. They now have a “hold” rating on the stock. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. Genus currently has a consensus rating of “Hold” and a consensus price target of GBX 1,401.29 ($22.98).
Genus plc is a United Kingdom-based company. The Company is engaged in applying quantitative genetics and biotechnology to animal breeding in the bovine and porcine sectors.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.